PRL-02
1 abstract
Abstract
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.Org: Carolina Urologic Research Center, Oncology Hematology Consultants Ltd., First Urology, Urology Cancer Center, PC, National Cancer Institute, Vilnius, Lithuania,